Product Information
TRESIBA FLEXTOUCH 200 UNIT/ML is a brand product labeled by Novo Nordisk, priced at $18.0703 per ML under NDC 00169255013. Its NADAC has been published 550 times since Mar 23, 2016.
Strength
200 U/mL
Manufacturer
Novo NordiskNDC
00169255013
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
INSULIN DEGLUDECApproval Type
Biologic (BLA)
FDA Application
BLA203314On Market Since
9/25/2015
Pharmacological Classes
Price Statistics
The NADAC for TRESIBA FLEXTOUCH 200 UNIT/ML has been published 550 times since Mar 23, 2016, and over the history we have for it it has declined 67.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $18.0703 per ML |
|---|---|
| All-time high | $65.1977 (Oct 16, 2019) |
| All-time low | $18.0613 (Jul 22, 2026) |
| 52-week high | $65.0504 |
| 52-week low | $18.0613 |
| Median price | $65.0267 |
| Average price | $59.9985 |
| Largest weekly change | -72.2% (Jan 14, 2026) |
| Weeks tracked | 550 |
| Tracking since | Mar 23, 2016 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novo Nordisk manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
insulin degludec market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Insulin Analog class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRESIBA FLEXTOUCH 200 UNIT/ML?
The current National Average Drug Acquisition Cost (NADAC) for TRESIBA FLEXTOUCH 200 UNIT/ML, manufactured by Novo Nordisk, is $18.0703 per ML (NDC 00169255013), effective Sep 30, 2026.
How has the price of TRESIBA FLEXTOUCH 200 UNIT/ML changed over time?
Over the history we have for it, the NADAC for TRESIBA FLEXTOUCH 200 UNIT/ML has declined 67.4%. It has been tracked across 550 weekly CMS publications since Mar 23, 2016.
What are the highest and lowest recorded NADAC prices for TRESIBA FLEXTOUCH 200 UNIT/ML?
Since Mar 23, 2016, the NADAC for TRESIBA FLEXTOUCH 200 UNIT/ML has ranged from a low of $18.0613 (Jul 22, 2026) to a high of $65.1977 (Oct 16, 2019), with a median of $65.0267 per ML.
Are there cheaper alternatives to TRESIBA FLEXTOUCH 200 UNIT/ML?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as TRESIBA FLEXTOUCH 200 UNIT/ML in a comparable dosage form, but none are currently priced below it.
Who manufactures TRESIBA FLEXTOUCH 200 UNIT/ML?
TRESIBA FLEXTOUCH 200 UNIT/ML (NDC 00169255013) is labeled by Novo Nordisk, and CMS classifies it as a brand product.